Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Daniel Hurni, Supply Chain Enterprise Capability Lead at Roche.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dan, covering:

 

Why working all over the world was a key competent in building his confidence, and his understanding of people and perspectives from different cultures.

The value of doing an MBA as a technician, and the need to master yourself and becoming the boss of yourself before leading others.

A behind the scenes peek of CDMO sourcing and selection at small and a big pharma across different modalities.... and the importance of relationship building.

Taking on a global supply chain lead at big pharma, and the job of navigating risk... and why you can only plan so much.

How he's excited by, and thinking about AI with respect to supply chain, and why he will only apply it where it makes sense.

Why listening, empathy, mentorship and networking are vital for survival and growth in a big pharma company.

Top tips for large and specialist CDMOs.

 

With over 20 years of experience driving operational transformation in the life sciences sector, Daniel has established a reputation for optimizing end-to-end supply chains and navigating the complexities of the global pharma and biotech landscape. Throughout his career, he has successfully led high-stakes initiatives—ranging from aseptic Tech Transfers for sterile drug products to large-scale M&A integrations—consistently delivering cost reductions and scalable, patient-centric solutions within complex matrix environments. In small and large pharmaceutical companies.

 

Daniel specializes in bridging the gap between digital innovation and physical operations, leveraging AI, data integration, and advanced analytics to enhance S&OP and network design. Beyond his technical leadership in manufacturing and supplier management, he is a seasoned change management architect, adept at aligning functional priorities with enterprise strategy to drive operational agility. Daniel is also a frequent collaborator and thought leader who focuses on mentoring cross-functional teams and influencing stakeholders at all levels to build the intelligent, resilient supply chains of the future.

 

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting

Firelli Alonso, Founder / Principal Consultant at ConsultFi Biologics LLC

Umar Hayat, Founder, CEO at Accanito Inc

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from Bora Nexus 2026. The event was hosted by Bora Pharmaceuticals and Molecule to Market,

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steve Favaloro, Chairman and CEO of Genezen.



Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steve, covering:



His deep passion for operations, and how early lessons in hard work and customer service shaped his leadership


Learning from Mark Bamforth and the entrepreneurial journey at Brammer Bio, culminating in a $1.7bn exit to Thermo Fisher


Why gaining exposure to every seat at the table was critical in preparing him for the CEO role


Building Genezen with a focus on strong values, hiring the right people and investing in differentiated capabilities


How the cell and gene therapy market has evolved over the past decade, and why he remains optimistic about the future of curative medicines


Why things inevitably go sideways in innovative drug development, and the importance of being prepared to navigate it



Steve Favaloro is an experienced biotech executive, board member, and investor. He is currently Chairman and CEO of Genezen, a best-in-class gene and cell therapy CDMO with specialized expertise in viral vector manufacturing. Steve joined Genezen in 2023 and has built up a team of almost 300 employees, supporting gene and cell therapy innovators from early-stage, growth-oriented biotechs to established industry leaders. He is an executive advisor at Ampersand Capital Partners, a leading healthcare investor, and serves on the board of Biologos. He also serves on the board of advisors of Life Science Cares Boston.



Prior to Genezen, Steve was CFO at Arbor Biotech, a next-generation gene editing therapeutic company. Steve also served as CFO at Arranta Bio, a leading CDMO for mRNA, from its founding in 2019 to its successful exit to Recipharm in February 2022. 



Prior to this, Steve was a finance leader and ultimately CFO at Brammer Bio, where he oversaw a period of rapid expansion and capital deployment from 2016 to 2019 – leading up to its successful sale to Thermo Fisher Scientific in May 2019 for $1.7B. Before joining Brammer, Steve held finance roles of increasing responsibility at MilliporeSigma, Merck KGaA, and Bruker Corporation. Steve received his MBA and Master of Science from the Carroll School of Management at Boston College. Steve also received his Bachelor of Arts degree in Economics from Boston College.



 



Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Felipe Furiati, Senior Director, External Supply Operations at Grünenthal.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Felipe, covering:

 

Why he stepped away from big pharma to pursue an MBA in the US and transition into top tier management consulting, broadening his global perspective

The pace and intensity of his time at Bain, and how it expanded his problem solving toolkit across industries

The challenges, risks and opportunities involved in acquiring products and integrating supply chains

How he approaches identifying, selecting and managing CDMO partners, and why product characteristics play a critical role

Building and maintaining a CMO and CDMO network, and the key criteria he uses to assess and source new projects

What strong vendor relationships really look like, why not every CDMO can be a strategic partner, and where CMOs can improve

 

Felipe currently works in External Supply Operations at Grünenthal, a mid-sized pharma organization with a vision of a world free of pain. He is an experienced professional in pharma strategy and operations, with a focus on external supply chain management across both pre launch and commercial products.

 

Originally from Brazil, Felipe has lived in Ireland and the United States, and is now based in Italy. His experience in the pharmaceutical industry is complemented by time in management consulting, where he gained exposure to a range of sectors including CPG and healthcare services.

 

Outside of work, Felipe is a mid of the pack endurance triathlete and enjoys spending time outdoors.

 

 

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tim Dietlin, Chief Executive Officer of ELIQUENT Life Science.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:

 

Practical advice on the mindset required when navigating M&A from both sides

Why he made the move from management consulting into executive search, and why it proved to be the right call

How the hunter became the hunted when private equity firm GHO Capital came knocking to take him to ELIQUENT

The challenge of integrating five successful businesses into one unified platform and brand

Timeless lessons on working with private equity, while balancing senior leadership with family life

Operating at the forefront of global regulatory change and the evolution of modern drug development

 

As Chief Executive Officer of ELIQUENT Life Sciences, Tim Dietlin steers the company’s global priorities and strategic growth. His leadership guides ELIQUENT’s team of unmatched regulatory experts and clears the path to better health.

 

Tim leads ELIQUENT’s global business with a focus on bringing clarity to regulatory complexity. His strategic direction leverages ELIQUENT’s combined capabilities and collective expertise to provide integrated solutions that bridge the spectrum of global regulatory challenges. Under his leadership, ELIQUENT’s platform of comprehensive solutions deliver a full-service engagement that global life sciences innovators need to gain and maintain market authorization for their products.

 

With more than 25 years of leadership experience, Tim empowers the ELIQUENT team to redefine regulatory excellence and provide continued value to clients. Prior to joining ELIQUENT, Tim served in leadership roles with premier firms advising and serving the life sciences industry, including Campbell Alliance, IBM and Heidrick & Struggles.   

 

Tim holds a BA from Loyola University Chicago, an MBA from DePaul University, and sits on the board of the Chicago chapter of the Juvenile Diabetes Research Foundation (JDRF).

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!